miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: With the identification of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) cells, EGFR-tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment in NSCLC. These inhibitors block auto-phosphorylation of activated EGFR by competing with ATP binding and mediate EGFR degradation independent of exogenous epidermal growth factor, which is associated with the mutation variants of EGFR. However, the precise mechanisms underlying the TKI-mediated EGFR degradation are still unclear. Materials and methods: To examine the physiological roles of miR-4487 and ubiquitin-specific peptidase 37 (USP37) in gefitinib-mediated EGFR degradation in NSCLC cells, multiple NSCLC cell lines were applied. The level of EGFR expression, apoptosis marker and autophagic flux were determined by western blot. Expression level of miR-4487 and cell cycle arrest was analyzed by TaqMan assay and flow cytometry respectively. Results: We found that gefitinib mediates EGFR degradation under normal culture conditions, and is dependent on autophagic flux and the mutation variants of EGFR. Gefitinib reduced expression levels of USP37, which mediated EGFR degradation similar to gefitinib. Our results also showed a gefitinib-mediated increase in endogenous miR-4487 level and presented evidence for the direct targeting of USP37 by miR-4487, resulting in the sequential enhancement of ubiquitination, autophagy, and EGFR degradation. Thus, the depletion of USP37 and overexpression of miR-4487 led to an increase in gefitinib-mediated apoptotic cell death. Conclusion: These data suggest that miR-4487 is a potential target for treating NSCLC, and miR-4487/USP37-regulated EGFR degradation is a determinant for developing gefitinib resistance.
Abstract
Purpose: With the identification of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) cells, EGFR-tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment in NSCLC. These inhibitors block auto-phosphorylation of activated EGFR by competing with ATP binding and mediate EGFR degradation independent of exogenous epidermal growth factor, which is associated with the mutation variants of EGFR. However, the precise mechanisms underlying the TKI-mediated EGFR degradation are still unclear. Materials and methods: To examine the physiological roles of miR-4487 and ubiquitin-specific peptidase 37 (USP37) in gefitinib-mediated EGFR degradation in NSCLC cells, multiple NSCLC cell lines were applied. The level of EGFR expression, apoptosis marker and autophagic flux were determined by western blot. Expression level of miR-4487 and cell cycle arrest was analyzed by TaqMan assay and flow cytometry respectively. Results: We found that gefitinib mediates EGFR degradation under normal culture conditions, and is dependent on autophagic flux and the mutation variants of EGFR. Gefitinib reduced expression levels of USP37, which mediated EGFR degradation similar to gefitinib. Our results also showed a gefitinib-mediated increase in endogenous miR-4487 level and presented evidence for the direct targeting of USP37 by miR-4487, resulting in the sequential enhancement of ubiquitination, autophagy, and EGFR degradation. Thus, the depletion of USP37 and overexpression of miR-4487 led to an increase in gefitinib-mediated apoptotic cell death. Conclusion: These data suggest that miR-4487 is a potential target for treating NSCLC, and miR-4487/USP37-regulated EGFR degradation is a determinant for developing gefitinib resistance.
참고문헌 (28)
- Sigismund S, "Emerging functions of the EGFR in cancer", Mol Oncol, 12, pp.3~20 (2018)
- Zhou X, "Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest", Anat Rec(Hoboken), 292, pp.1122~1127 (2009)
- Dragowska WH, "Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer", PLoS One, 8, pp.e76503~ (2013)
- Liu Z, "Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer", PLoS One, 12, pp.e0177694~ (2017)
- Han W, "EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells", PLoS One, 6, pp.e18691~ (2011)
- Singh R, "Autophagy in the cellular energetic balance", Cell Metab, 13, pp.495~504 (2011)
- Shaid S, "Ubiquitination and selective autophagy", Cell Death Differ, 20, pp.21~30 (2013)
- Pinilla-Macua I, "EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo", Elife, 6, pp.e31993~ (2017)
- Citri A, "Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases : implications for cancer therapy", EMBO J, 21, pp.2407~2417 (2002)
- Sacco JJ, "Emerging roles of deubiquitinases in cancer-associated pathways", IUBMB Life, 62, pp.140~157 (2010)
- Qin T, "Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity", J Exp Clin Cancer Res, 37, pp.287~ (2018)
- Hong K, "USP37 promotes deubiquitination of HIF2alpha in kidney cancer", Proc Natl Acad Sci U S A, 117, pp.13023~13032 (2020)
- Pan J, "USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer", Oncogene, 34, pp.3957~3967 (2015)
- Cai J, "USP37 promotes lung cancer cell migration by stabilizing snail protein via deubiquitination", Front Genet, 10, pp.1324~ (2019)
- Pascut D, "A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients", Sci Rep, 9, pp.8265~ (2019)
- Chen Y, "Identification of ULK1 as a novel biomarker involved in miR-4487 and miR-595 regulation in neuroblastoma SH-SY5Y cell autophagy", Sci Rep, 5, pp.11035~ (2015)
- Ono M, "Sensitivity to gefitinib(Iressa, ZD1839)in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor(EGF)receptor", extracellular signal-regulated kinase 1, Akt pathway for proliferation, pp.Mol Cancer Ther, 2004[DOI]
- Ray P, "Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance", J Biol Chem, 295, pp.12661~12673 (2020)
- Lemmon MA, "Cell signaling by receptor tyrosine kinases", Cell, 141, pp.1117~1134 (2010)
- Chung BM, "Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src", BMC Cell Biol, 10, pp.84~ (2009)
- Henriksen L, "Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands", PLoS One, 8, pp.e58148~ (2013)
- Ray P, "Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors", Oncotarget, 7, pp.68597~68613 (2016)
- Stark MS, "The prognostic and predictive value of melanoma-related microRNAs using tissue and serum : a microRNA expression analysis", EBioMedicine, 2, pp.671~680 (2015)
- Hu L, "The emerging role of microRNA-4487", 6845-3p in Alzheimer’s disease pathologies is induced by Abeta25-35 triggered in SH-SY5Y cell, 2018, pp.12, 119~
- Chen S, "Autophagy facilitates the lapatinib resistance of HER2 positive breast cancer cells", Med Hypotheses, 77, pp.206~208 (2011)
- Bjorkoy G, "p62", SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death, 2005, pp.171, 603~614
- Kirkin V, "A role for NBR1 in autophagosomal degradation of ubiquitinated substrates", Mol Cell, 33, pp.505~516 (2009)
- Dobson TH, "Regulation of USP37 expression by REST-associated G9a-dependent histone methylation", Mol Cancer Res, 15, pp.1073~1084 (2017)